Cargando…
Cyclosporine is a potential curative treatment option for advanced thymoma
BACKGROUND: Thymectomy can effectively cure most thymoma patients; however, patients with advanced thymoma typically require chemotherapy, which is associated with limited efficacy in this context. Here we provide the first report of a patient with recurrent thymoma who achieved complete remission (...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415741/ https://www.ncbi.nlm.nih.gov/pubmed/28473943 http://dx.doi.org/10.1186/s40164-017-0073-6 |
_version_ | 1783233581892501504 |
---|---|
author | Isshiki, Yusuke Tanaka, Hiroaki Suzuki, Yoshio Yoshida, Yukihiro |
author_facet | Isshiki, Yusuke Tanaka, Hiroaki Suzuki, Yoshio Yoshida, Yukihiro |
author_sort | Isshiki, Yusuke |
collection | PubMed |
description | BACKGROUND: Thymectomy can effectively cure most thymoma patients; however, patients with advanced thymoma typically require chemotherapy, which is associated with limited efficacy in this context. Here we provide the first report of a patient with recurrent thymoma who achieved complete remission (CR) using cyclosporine therapy. CASE PRESENTATION: A 63-year-old woman who had undergone resection surgery for recurrent type B1 thymoma developed pure red cell aplasia (PRCA), and CT findings revealed thymoma recurrence. After the initiation of orally-administered cyclosporine, PRCA quickly resolved, and the thymoma disappeared without the administration of any anti-thymoma therapy. The patient has remained in CR for over 3 years using only cyclosporine. CONCLUSIONS: This is the first report describing the curative potential of cyclosporine for the treatment of advanced thymoma. Although the mechanism underlying this effect remains unclear, cyclosporine can become a less toxic and more cost-effective treatment option for thymoma compared with conventional therapy. Clinical trials are needed to confirm the therapeutic potential of cyclosporine as a new treatment option for thymoma. |
format | Online Article Text |
id | pubmed-5415741 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54157412017-05-04 Cyclosporine is a potential curative treatment option for advanced thymoma Isshiki, Yusuke Tanaka, Hiroaki Suzuki, Yoshio Yoshida, Yukihiro Exp Hematol Oncol Case Report BACKGROUND: Thymectomy can effectively cure most thymoma patients; however, patients with advanced thymoma typically require chemotherapy, which is associated with limited efficacy in this context. Here we provide the first report of a patient with recurrent thymoma who achieved complete remission (CR) using cyclosporine therapy. CASE PRESENTATION: A 63-year-old woman who had undergone resection surgery for recurrent type B1 thymoma developed pure red cell aplasia (PRCA), and CT findings revealed thymoma recurrence. After the initiation of orally-administered cyclosporine, PRCA quickly resolved, and the thymoma disappeared without the administration of any anti-thymoma therapy. The patient has remained in CR for over 3 years using only cyclosporine. CONCLUSIONS: This is the first report describing the curative potential of cyclosporine for the treatment of advanced thymoma. Although the mechanism underlying this effect remains unclear, cyclosporine can become a less toxic and more cost-effective treatment option for thymoma compared with conventional therapy. Clinical trials are needed to confirm the therapeutic potential of cyclosporine as a new treatment option for thymoma. BioMed Central 2017-05-03 /pmc/articles/PMC5415741/ /pubmed/28473943 http://dx.doi.org/10.1186/s40164-017-0073-6 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Isshiki, Yusuke Tanaka, Hiroaki Suzuki, Yoshio Yoshida, Yukihiro Cyclosporine is a potential curative treatment option for advanced thymoma |
title | Cyclosporine is a potential curative treatment option for advanced thymoma |
title_full | Cyclosporine is a potential curative treatment option for advanced thymoma |
title_fullStr | Cyclosporine is a potential curative treatment option for advanced thymoma |
title_full_unstemmed | Cyclosporine is a potential curative treatment option for advanced thymoma |
title_short | Cyclosporine is a potential curative treatment option for advanced thymoma |
title_sort | cyclosporine is a potential curative treatment option for advanced thymoma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415741/ https://www.ncbi.nlm.nih.gov/pubmed/28473943 http://dx.doi.org/10.1186/s40164-017-0073-6 |
work_keys_str_mv | AT isshikiyusuke cyclosporineisapotentialcurativetreatmentoptionforadvancedthymoma AT tanakahiroaki cyclosporineisapotentialcurativetreatmentoptionforadvancedthymoma AT suzukiyoshio cyclosporineisapotentialcurativetreatmentoptionforadvancedthymoma AT yoshidayukihiro cyclosporineisapotentialcurativetreatmentoptionforadvancedthymoma |